Geode Capital Management LLC Has $11.43 Million Holdings in Phibro Animal Health Co. (NASDAQ:PAHC)

Geode Capital Management LLC grew its holdings in Phibro Animal Health Co. (NASDAQ:PAHC) by 5.7% during the third quarter, Holdings Channel.com reports. The firm owned 507,469 shares of the company’s stock after buying an additional 27,201 shares during the period. Geode Capital Management LLC’s holdings in Phibro Animal Health were worth $11,430,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Phibro Animal Health in the third quarter worth $70,000. Quantbot Technologies LP bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. increased its holdings in Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after buying an additional 1,522 shares during the last quarter. CWM LLC raised its position in Phibro Animal Health by 190.8% during the third quarter. CWM LLC now owns 6,363 shares of the company’s stock valued at $143,000 after acquiring an additional 4,175 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Phibro Animal Health in the second quarter valued at approximately $193,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of recent research reports. Barclays raised their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. StockNews.com cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 27th. Finally, Morgan Stanley increased their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $21.00 on Wednesday. The company has a market capitalization of $850.56 million, a PE ratio of 48.84, a price-to-earnings-growth ratio of 0.58 and a beta of 0.51. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. Phibro Animal Health Co. has a one year low of $10.03 and a one year high of $25.98. The company’s fifty day moving average price is $23.17 and its 200 day moving average price is $20.94.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th were paid a $0.12 dividend. The ex-dividend date was Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 2.29%. Phibro Animal Health’s payout ratio is presently 111.63%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.